Showing results (1-10 of 441) with videos related to

Sort By:
Pageof 45
Rinsho Byori. the Japanese Journal of Clinical Pathology|December 24, 2005
[Detection of antibodies specific for blood group antigens A and B]Kimiko Yurugi, Shinya Kimura, Taira Maekawa
International Journal of Clinical Oncology|October 12, 2007
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemiasTaira Maekawa, Eishi Ashihara, Shinya Kimura
Current Pharmaceutical Biotechnology|November 2, 2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaShinya Kimura, Eishi Ashihara, Taira Maekawa
International Journal of Cancer|March 15, 2008
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplificationKoji Morinaga, Takahiro Yamauchi, Shinya Kimura, et al.
Current Medicinal Chemistry|August 19, 2007
Zoledronic acid - a multiplicity of anti-cancer actionTakeshi Yuasa, Shinya Kimura, Eishi Ashihara, et al.
Cancer Cell International|April 6, 2013
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cellsSeiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Chemistry & Biology|June 25, 2011
Identification of a small-molecule inhibitor of DNA topoisomerase II by proteomic profilingMakoto Kawatani, Hiroshi Takayama, Makoto Muroi, et al.
Plos One|March 4, 2014
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemiaSeiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, et al.
Leukemia Research|January 15, 2008
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell linesYasuyuki Deguchi, Shinya Kimura, Eishi Ashihara, et al.
Cancer Biology & Therapy|October 9, 2013
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutationSeiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Pageof 45